Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ondine Biomedical Inc

Healthcare GB OBI

12.75GBX
-0.25(1.92%)

Last update at 2026-06-11T15:04:00Z

Day Range

12.5013.50
LowHigh

52 Week Range

7.5018.50
LowHigh

Fundamentals

  • Previous Close 13.00
  • Market Cap58.30M
  • Volume317216
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-23.71400M
  • Revenue TTM2.20M
  • Revenue Per Share TTM0.006
  • Gross Profit TTM 1.45M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -19.09800M -14.41200M -19.37200M -50.08500M -16.20700M
Minority interest - - - - 0.00200M
Net income -19.09800M -14.41200M -20.78400M -82.81600M -16.91700M
Selling general administrative 9.93M 8.01M 10.91M 12.97M 10.40M
Selling and marketing expenses 1.08M 1.79M 1.40M 0.36M 1.63M
Gross profit 1.32M 0.70M 0.29M 1.25M 0.65M
Reconciled depreciation 0.56M 0.59M 0.49M 0.51M 1.22M
Ebit -19.05100M -14.37400M -18.76300M -17.52000M -15.87100M
Ebitda -18.48600M -13.78700M -17.43700M -16.84000M -14.27500M
Depreciation and amortization 0.56M 0.59M 1.33M 0.68M 1.60M
Non operating income net other - - - - -
Operating income -19.44400M -14.80500M -18.76300M -17.52000M -15.87100M
Other operating expenses 21.49M 16.01M 19.40M 20.09M 17.66M
Interest expense 0.05M 0.04M 0.03M 1.20M 0.49M
Tax provision - - - 0.00000M -
Interest income 0.03M 0.24M 0.19M - -
Net interest income -0.01500M 0.20M 0.16M -1.19900M -0.49100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.09M 1.41M 32.73M 0.71M
Total revenue 2.05M 1.20M 0.64M 2.57M 1.79M
Total operating expenses 20.77M 15.51M 19.05M 18.77M 16.52M
Cost of revenue 0.73M 0.50M 0.35M 1.31M 1.14M
Total other income expense net 0.35M 0.39M -0.60900M -32.56500M -0.33600M
Discontinued operations - - - - -
Net income from continuing ops -19.09800M -14.41200M -19.37200M -50.08500M -16.20700M
Net income applicable to common shares - - - -50.08500M -16.27100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 12.82M 5.73M 16.57M 34.14M 2.63M
Intangible assets - - - - 0.17M
Earning assets - - - - -
Other current assets 0.64M 0.38M - 2.08M 0.72M
Total liab 5.95M 3.65M 4.92M 4.48M 36.46M
Total stockholder equity 6.88M 2.08M 11.64M 29.66M -33.81400M
Deferred long term liab - - - - -
Other current liab 4.19M 1.75M 3.16M 2.08M 3.00M
Common stock 262.60M 239.65M 235.04M 235.04M 119.53M
Capital stock 262.60M 239.65M 235.04M 235.04M 119.53M
Retained earnings -285.43200M -266.33400M -251.92200M -232.54400M -182.13600M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.04M 0.05M
Cash 9.77M 2.98M 13.12M 30.36M 0.63M
Cash and equivalents - - - - -
Total current liabilities 5.95M 3.49M 3.91M 3.92M 35.78M
Current deferred revenue - - - - 1.18M
Net debt -9.59900M -2.44000M -12.22900M -29.62600M 30.83M
Short term debt 0.17M 0.38M 0.36M 0.65M 31.37M
Short long term debt - - 0.00000M 0.50M 34.15M
Short long term debt total 0.17M 0.54M 0.90M 0.74M 31.46M
Other stockholder equity 29.71M 28.77M 28.52M 27.16M 28.79M
Property plant equipment - - - 0.60M 0.67M
Total current assets 12.19M 4.75M 15.13M 33.50M 1.75M
Long term investments - - - - -
Net tangible assets - - - 29.66M -33.98500M
Short term investments - - - - -
Net receivables 0.51M 0.33M 0.13M 0.25M 0.54M
Long term debt - - - - -
Inventory 1.27M 1.07M 1.29M 1.06M 0.40M
Accounts payable 1.59M 1.36M 0.39M 1.20M 0.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.04M 0.04M 0.04M 0.04M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 0.63M 0.98M 1.44M 0.64M 0.89M
Capital lease obligations 0.17M 0.54M 0.90M 0.24M 0.31M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.01000M -0.17700M -0.31100M -0.07700M 2.90M
Change to liabilities - - 0.25M 2.15M 0.26M
Total cashflows from investing activities -0.01000M -0.17700M - -0.07700M -0.09900M
Net borrowings 1.12M -0.04000M - 6.14M 3.83M
Total cash from financing activities 21.74M 3.79M -0.27500M 41.90M 3.83M
Change to operating activities - - 0.13M -1.64500M -0.18400M
Net income -19.09800M -14.41200M -19.37200M -50.08500M -16.27100M
Change in cash 6.79M -10.13400M -16.59600M 29.24M 0.32M
Begin period cash flow 3.14M 13.27M 29.87M 0.63M 0.31M
End period cash flow 9.93M 3.14M 13.27M 29.87M 0.63M
Total cash from operating activities -15.49000M -13.65300M -16.34500M -12.54000M -6.33100M
Issuance of capital stock 22.98M 4.91M 0.00000M 37.73M -
Depreciation 0.56M 0.59M 0.49M 0.51M 1.22M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.32800M 0.10M -0.33700M -0.67300M 0.09M
Change to account receivables -0.18500M -0.14200M 0.07M 0.30M -0.52000M
Sale purchase of stock - - 0.00000M -0.79900M -
Other cashflows from financing activities -2.36000M -1.08700M -0.31100M 5.66M 2.90M
Change to netincome - - 1.10M 36.90M 9.15M
Capital expenditures 0.01000M 0.18M 0.31M 0.08M 0.10M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.91M -0.29800M 0.10M 0.13M -0.36100M
Stock based compensation 1.22M 0.64M 1.45M 3.91M 8.15M
Other non cash items -0.08600M -0.17000M 0.99M 1.36M 0.83M
Free cash flow -15.50000M -13.83000M -16.65600M -12.61700M -6.43000M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OBI
Ondine Biomedical Inc		 -0.25 1.92% 12.75 - - 26.47 14.64 44.46 -0.4316
GNS
Genus PLC		 28.00 1.29% 2198.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 2.00 1.67% 122.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 7.00 1.15% 617.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 68.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.

Ondine Biomedical Inc

1100 Melville Street, Vancouver, BC, Canada, V6E 4A6

Key Executives

Name Title Year Born
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA Founder, CEO & Director NA
Dr. Nicolas G. Loebel Ph.D. Pres, CTO & Director NA
Mr. Thomas Dawson Sr. VP of Corp. Devel. NA
Mr. Vipul Shah VP & CFO NA
Mr. Mike Long VP of Operations NA
Angelika Vance VP of Corp. Communications NA
Ms. Carolyn M. Cross C.F.A., M.B.A. Founder, CEO & Executive Director NA
Dr. Nicolas G. Loebel Ph.D. President, CTO & Executive Director NA
Mr. Alan Thomas Non-Board Interim CFO NA
Ms. Angelika Vance Vice President of Corporate Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.